Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis
Augustin, Matthias (University Medical Center Hamburg-Eppendorf)
Gottlieb, Alice B. (Icahn School of Medicine at Mount Sinai (Nova York, Estats Units d'Amèrica))
Lebwohl, Mark (Icahn School of Medicine at Mount Sinai (Nova York, Estats Units d'Amèrica))
Pinter, Andreas (University Hospital of Frankfurt (Alemanya))
Warren, Richard B. (Manchester University NHS Foundation Trust)
Puig Sanz, Lluís (Institut de Recerca Sant Pau)
Warham, Rhys (UCB, Slough, UK)
Lambert, Jérémy (UCB, Colombes, France)
Wiegratz, Susanne (UCB, Monheim am Rhein, Germany)
Szilagyi, Balint (UCB, Monheim am Rhein, Germany)
Blauvelt, Andrew (Oregon Medical Research Center)
Universitat Autònoma de Barcelona. Departament de Medicina

Date:	2024
Abstract:	With newer biologics, the achievement of complete skin clearance has become an attainable treatment goal for patients with plaque psoriasis. We evaluate how improvements in Psoriasis Area and Severity Index (PASI) responses, particularly at incremental improvements approaching complete skin clearance (PASI 100), translate into improvements in health-related quality of life (HRQoL) and patient-perceived symptoms. Data from the BE RADIANT phase 3b trial (NCT03536884) and its open-label extension (OLE), pooled across all study visits and treatments over 16 weeks (randomised patients) and 2 years (patients entering the OLE), were analysed using mixed-effects logistic regression models. Proportions of patients achieving a Dermatology Life Quality Index (DLQI) of 0/1, DLQI item scores of 0, and Psoriasis Symptoms and Impacts Measure (P-SIM) item scores of 0 for itching, scaling, and skin pain at specific PASI improvement levels were estimated. Seven hundred and forty-three patients were randomised to treatment; 654 entered the OLE. Using 16-week pooled data, there were incremental improvements in the proportions of patients estimated by our model to achieve DLQI 0/1 with PASI 100 compared with 95% (PASI = 95%) and 90% (PASI = 90%) improvements in PASI (93. 0%, 89. 3%, and 83. 8% achieving DLQI 0/1, respectively). Estimated proportions achieving DLQI item scores of 0 had the greatest increases at higher PASI improvement levels for Items 1 (itchy, sore, painful, or stinging skin), 2 (embarrassment), and 4 (choice of clothing). Estimated proportions of patients achieving P-SIM = 0 were also higher for PASI 100 (itching: 61. 7%; scaling: 82. 2%; skin pain: 96. 9%) than for PASI = 95% (50. 8%; 72. 3%; 95. 7%) and PASI = 90% (39. 8%; 59. 5%; 94. 0%). Similar benefits of incremental PASI improvements were estimated using 2-year data. Complete skin clearance translated into the greatest benefits to HRQoL and patient-perceived symptoms, over and above skin clearance between 90% and 100%, highlighting the importance of targeting PASI 100 as a treatment outcome for patients with psoriasis.
Note:	Altres ajuts: UCB (NCT03536884); NIHR Manchester Biomedical Research Centre (NIHR203308)
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Biologics ; Clinical trials ; Psoriasis ; Quality of life
Published in:	Dermatology and Therapy, Vol. 14, Núm. 10 (October 2024) , p. 2841-2857, ISSN 2190-9172

DOI: 10.1007/s13555-024-01261-6
PMID: 39285121

17 p, 2.6 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles